Drug Approval | January 21, 2022
Bristol Myers Squibb receives approval for Abecma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
It provides Covid-19 detection and Omicron surveillance in less than two hours
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Subscribe To Our Newsletter & Stay Updated
